Abivax Closes Initial Public Offering on the Nasdaq Global Market
FinSMEs
OCTOBER 24, 2023
Abivax SA (Euronext Paris: FR0012333284 – ABVX), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, closed its previously announced initial public offering on the Nasdaq Global Market.
Let's personalize your content